

References

I-30

1. Lipton A, Fizazi K, Stopeck A, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. *Eur J Cancer*. 2016;53:75-83.
2. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer*. 2016:447-455.
3. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. *Future Oncol*. 2015;2865-2871.
4. Prolia (denosumab) injection for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 01/2023.
5. Xgeva (denosumab) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 06/2020.
6. Shapiro CL, Moriarty JP, Dusetzine S, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). *J Clin Oncol*. 2017; 35:3949-3955.
7. National Comprehensive Cancer Network (NCCN). Denosumab. NCCN Drugs and Biologics Compendium®. 2023.
8. Micromedex DrugDex Compendium®. 2023. Denosumab.
9. Clinical Pharmacology™ Compendium.2023.Tampa FL: Gold Standard, Inc. Denosumab.
10. Deveci MA, Paydas S, Gonlusen G, et al. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. *Acta Orthop Traumatol Turc*. 2017;51;1-6.
11. Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. *Clin Chem*. 2017;63(2):464-474.
12. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheumatol*. 2017;69(8):1521-1537.
13. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *P T*. 2018;43(2):92-104.
14. Barrioneuvo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*.2019;104(5):1623-1630.

15. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab.* 2020;105(3):587-594.
16. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. *Am Fam Physician.* 2015;92(4):261-268.
17. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al: Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2017;35(18):2062-2081.
18. Denosumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 2, 2022.
19. Camacho P M, Petak S M, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. *Endocrine Practice.* 2020; 26(1): 1-46.
20. Qaseem A, Forciea MA , McLean RM, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med.*2017;166 (11):818-839.